COR US S&P 500Russell 1000 Konferencja wynikowa
Cencora
Wyniki II kw. 2026 vs I kw. 2026 · poprzedni kwartał · rok obrotowy: Q3 2026 · opublikowano 5 sie 2026 i 6 maj 2026
Net income down 53.5% on the previous quarter, guidance raised. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
1 · Liczby
−53,5%
Zysk netto vs I kw. 2026
Prognoza podniesiona
Zysk netto 763,5 mln vs 1,64 mld
Przychody +8,2%
Against the same quarter last year (II kw. 2025) it is +11.1%, so the move on last quarter looks seasonal or timing-related rather than a trend.
2 · Jak mówił zarząd
Typowy
More upbeat than 63% of company calls
Answers to analysts: typical, in line with the script.
Similar to last call.
3 · Co się wyróżniło
Prognoza ↑
COR raised fiscal 2026 adjusted EPS guidance to $17.75 to $17.95, citing confidence in continued execution and year-to-date performance.
Między wierszami
-
Prognoza
International Healthcare Solutions revenue growth is now expected to be approximately 8% at the low end of the previous range due to stronger demand.
Cytat ze źródła
“In the International Healthcare Solutions segment, we now expect revenue growth to be approximately 8% at the low end of our previous range as a result of the stronger...”
-
Liczba
The company achieved double-digit adjusted operating income growth and completed $1 billion of opportunistic share repurchases during the third quarter of 2026.
Cytat ze źródła
“Our business performance drove double-digit adjusted operating income growth and supported by $1 billion of opportunistic share repurchases, we achieved...”
-
Słabnie
Excluding the loss, as you said, of Florida Cancer and the contribution from OneOncology, Cencora's operating income growth was up double…
Cytat ze źródła
“Excluding the loss, as you said, of Florida Cancer and the contribution from OneOncology, our operating income growth was up double... ...did outperform our expectations, demonstrating the strength of their platform and its ability to attract physicians to the MSO, which we benefited from overall distribution and GPOs for some time. I'll let turn it over to Bob on 2027.”
-
Słabnie
COR now expects International Healthcare Solutions revenue growth of approximately 8%, at the low end of its previous range.
Cytat ze źródła
“The critical role we play in the pharmaceutical supply chain and the investments we are making allow us to capitalize... reflecting the strength of our business and execution to drive sustainable long-term growth. As we look to the balance of the fiscal year and beyond, our focused strategy guided by our purpose, growth priorities and performance drivers positions us to continue creating value for all our stakeholders.”
Wycena
Odwrócony DCF. Wolne przepływy pieniężne z ostatniego pełnego roku obrotowego (2025-09-30), powiększane przez 10 lat, zdyskontowane, plus wartość rezydualna. „Wzrost implikowany” to tempo, które zakłada obecna cena.
Aktualna cena
$317.25
zamknięcie z 2026-10-07
Rynek zakłada wzrost o iRoczny wzrost wolnych przepływów pieniężnych przez następne 10 lat, który zakłada dzisiejsza cena akcji. Jeśli uważasz, że spółka będzie rosła szybciej, akcja jest w tym modelu tania; wolniej — droga.
+7,2% przez 10 lat
Wartość godziwa / akcję
—
Kupuj poniżej
—
Cena vs wartość godziwa
—
Cena vs cena zakupu
—
Zarząd oczekuje
Przychody +8% · z raportu za II kw. 2026: “International Healthcare Solutions revenue growth is now expected to be approximately 8% at the low end of the previous range due to stronger demand.”
Prognoza zarządu, zwykle na rok do przodu — nie tempo wzrostu przepływów na 10 lat.
Ton
Jak optymistyczny był język w porównaniu z innymi spółkamiiTon to liczba pozytywnych słów finansowych minus liczba negatywnych, skorygowana o długość tekstu. Zarządy zwykle mówią pozytywnie, więc etykiety porównują każdą konferencję z ostatnimi konferencjami wszystkich spółek: „typowy” to środkowa trzecia, „bardzo optymistyczny” to najlepsze 10%, „ostrożny” to najsłabsze 10%.. Kropka: II kw. 2026. Pierścień: I kw. 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Zdania, które wpłynęły na ton
“As I look to fiscal 2027 and beyond, I'm excited to further Cencora's strong track record of execution and disciplined capital stewardship to drive durable shareholder value creation.”
“Moving to our digital transformation, where we're combining business process improvement and technology advances to improve how we operate and work with partners across the health care system.”
“Our business performance drove double-digit adjusted operating income growth and supported by $1 billion of opportunistic share repurchases, we achieved 12% EPS growth in the quarter.”
Liczby
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Pozycja | II kw. 2026period end 2026-06-30 | I kw. 2026period end 2026-03-31 | Zmiana | II kw. 2025 | r/r |
|---|---|---|---|---|---|
| Przychody | 84,75 mld | 78,36 mld | +8,2% | 80,66 mld | +5,1% |
| Zysk brutto ze sprzedaży | 3,61 mld | 3,59 mld | +0,5% | 2,91 mld | +24,1% |
| Zysk operacyjny | 1,12 mld | 1,14 mld | −2,0% | 867,7 mln | +29,1% |
| Zysk netto | 763,5 mln | 1,64 mld | −53,5% | 687,4 mln | +11,1% |
| Zysk na akcję | 3,94 | 8,40 | −53,1% | 3,52 | +11,9% |
| C/Z dziś 23,4 | 21,0 | 24,1 | −3,1 | 30,8 | −9,8 |
Tematy
Najczęściej omawiane teraz
- I look forward to closely working with Eva as Cencora continues building upon its track record of execution, growth and...
- As Cencora saw last quarter with its large mail order customer that may be in-sourced.
- There is a meaningful clinical trial activity within OneOncology, but there's significant opportunity for growth.
- You can think about analytics-type solutions and insights that Cencora will be providing.
- As Cencora looks ahead, it remains confident in its ability to deliver continued growth in its U.S.
Zniknęło od I kw. 2026
- Słabnie In other, Cencora saw 5% growth driven by MWI and pro forma and so you ask kind of what is...
- Zniknęło Every day, Cencora's teams move millions of medications through the supply chain to thousands of health care sites, creating significant...
- Słabnie Of all, to the first part of your question, and Cencora was pleased to see the core operating income...
- Słabnie To the extent that the mail order pharmacies and PBMs have selection choice over the biosimilar, and that could go...
Najnowsze komunikaty
Oficjalne raporty spółki, od najnowszych.
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Director or officer change · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Material agreement; New financial obligation · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K